| Document |
Document Title |
|
WO/2010/090305A1 |
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...
|
|
WO/2010/088862A1 |
Disclosed is a method for preparing 7-halo-2-oxo-heptylate, an intermediate of cilastatin. The main steps are as follows: A. Addition reaction, in which 6-halo-hexanal is reacted with a cyanide to obtain 7-halo-α-hydroxyl-heptonitril; B...
|
|
WO/2010/079668A1 |
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R1, R2, R2', R4, R5, R6, R7, R8 and R8' each represents a hydrogen atom or the like; and R3 represents a hydrogen...
|
|
WO/2010/071988A1 |
Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 subs...
|
|
WO/2010/074332A2 |
There is provided a sulfur-containing compound having a controlling effect on arthropod pests represented by the formula (I): wherein m represents 1, 2 or 3; n represents 0, 1 or 2; A represents an optionally substituted C2-C10 fluoroalk...
|
|
WO/2010/069859A1 |
The invention is concerned with novel compound of formula (I) wherein R, R2 and Q are as defined in the description and in the claims, and pharmaceutically acceptable salts thereof, processes for their preparation, their use as pharmaceu...
|
|
WO/2010/068531A1 |
A perfluoropolyether thiol compound comprises a perfluoropolyether segment, at least one mercapto group (-SH), and at least one intervening divalent carbonylimino moiety (-C(=O)-NR-, wherein R is hydrogen or alkyl). The compound can be p...
|
|
WO/2010/063767A1 |
The invention relates to compounds of the general formula (I) wherein the variable have the meanings as indicated in the claims, and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They...
|
|
WO/2010/058129A2 |
The present invention relates to a method for manufacturing methylmercaptopropionaldehyde (MMP) including at least the following steps: (a) dehydrating glycerol to acrolein from an aqueous solution of glycerol in the presence of an acid ...
|
|
WO/2010/055911A1 |
A compound represented by formula (I) or a salt thereof, which is useful as an agent for treatment or prevention of various epileptic seizures, namely partial seizures and/or generalized seizures. (In the formula, R1, R2 and R3 may be th...
|
|
WO/2010/056855A1 |
Provided are processes for preparation of Retapamulin via its pleuromutilin-thiol precursor
|
|
WO/2010/053902A2 |
Disclosed herein are novel compounds and pharmaceutical compositions comprising these compounds. In some embodiments, the compounds are inhibitors of the tryptase enzyme and are useful for treating allergic rhinitis, asthma, vascular inj...
|
|
WO/2010/050435A1 |
Disclosed is a novel cyclohexylamine derivative containing a phenyl group, which is useful as a novel sigma receptor ligand. Also disclosed is a therapeutic agent for diseases accompanied by central nervous system disorders, which compr...
|
|
WO/2010/049768A1 |
Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases ...
|
|
WO/2010/041425A1 |
Provided is a novel method for producing a peptide employing a ligation reaction, which shows more efficient ligation than prior native chemical ligation employing a thiol auxilliary group and does not tend to give rise to side reactions...
|
|
WO/2010/034118A1 |
There is provided amino acid ester compounds comprising at least one nitric oxide releasing group, pharmaceutically acceptable salts thereof and compositions thereof. These compounds involve an amino acid side-chain or an amino acid deri...
|
|
WO/2010/032771A1 |
Disclosed is a novel amino acid derivative having excellent analgesic activity. The amino acid derivative is a novel compound which exhibits excellent analgesic activity not only with respect to nociceptive pain model animals, but also w...
|
|
WO/2010/030787A1 |
The invention described herein discloses bisphenol alkane compounds of formulae III and Vl and similar compounds as well as 4-[4-hydroxybenzylthio]- phenol compounds which are estrogen receptor ligands, composition containing these compo...
|
|
WO/2010/028088A2 |
Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
|
|
WO/2010/027051A1 |
Disclosed is a novel intermediate for producing a substituted isoxazoline compound that is useful as a harmful organism control agent. Specifically disclosed are: a substituted acetophenone compound represented by general formula (1) or ...
|
|
WO/2010/025482A1 |
Compounds of formula (I), which are 14-O-{[(optionally substituted hydroxy)cyclohexyl)sulfanyl]acetyl}mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical composition...
|
|
WO/2010/021351A1 |
Disclosed is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonistic) activity. Specifically disclosed is a compound represented by general formula (1) [wherei...
|
|
WO/2010/018113A2 |
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present inventio...
|
|
WO/2010/016011A1 |
Organosulfur compounds of the general formula (2) are described, wherein R1 and R2 are linear or branched C1- C5 alkyl; linear or branched C1- C5 alkenyl with the proviso that R1 is not prop-1-enyl (allyl); substituted linear or branched...
|
|
WO/2010/013567A1 |
Disclosed is a pest control agent having an excellent effect, which contains, as an active ingredient, a compound represented by general formula (1). (In the formula, A represents a carbon atom, a nitrogen atom or the like; K represents...
|
|
WO/2010/014943A2 |
Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, an...
|
|
WO/2010/010959A1 |
An ester compound of the formula (1): wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a 1-propenyl group, a 2- methyl-1-propenyl group or a 2-cyano-l-propenyl group.
|
|
WO/2010/011523A2 |
Described are multi-ring antioxidant products comprising at least one sulfur- bridged aromatic hydrocarbon compound substituted on at least one of its aromatic rings by at least one sterically hindered 3,5-dihydrocarbyl-4-hydroxybenzyl m...
|
|
WO/2010/006725A1 |
A compound of formula (I) wherein A1, A2, A3, A4, G1, G2, R1, R2, L, Q1, and Q2 are as defined in claim 1; or a salt or N- oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds o...
|
|
WO/2010/003127A2 |
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists Of PGD2 receptors. Also described here...
|
|
WO/2010/003120A2 |
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combi...
|
|
WO/2009/156620A1 |
The degradation of an absorbent solution comprising organic compounds provided with an amino functional group, in aqueous solution, is substantially reduced in the presence of a small amount of multisulphur‑containing degradation-inhib...
|
|
WO/2009/156622A1 |
The degradation of an absorbing solution containing organic compounds having an amine function in aqueous solution is substantially reduced in the presence of a small quantity of sulphurated degradation inhibiting agents defined by gener...
|
|
WO/2009/157196A1 |
Disclosed is a compound having GPR52 agonist activity and serving as an agent for preventing or treating schizophrenia or the like. Specifically disclosed is a compound represented by formula (I) or a salt thereof. In the formula, A repr...
|
|
WO/2009/156621A1 |
The degradation of an absorbent solution comprising organic compounds provided with an amino functional group, in aqueous solution, is substantially reduced in the presence of a small amount of sulphur‑containing degradation-inhibiting...
|
|
WO/2009/155362A1 |
Compounds with physiological effects, such as the activation of hematopoietic growth factor receptors, are disclosed. These compounds can be used to treat a variety of conditions, diseases and ailments, including hematopoietic conditions...
|
|
WO/2009/150524A1 |
Disclosed is a process for preparing anti-inflammatory compound nepafenac comprising preparing a compound of formula (V) wherein a N-halosuccinimide is used as the halogenating agent, followed by desulfurization using Raney Nickel. Also ...
|
|
WO/2009/151770A2 |
Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof.
|
|
WO/2009/145996A2 |
The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and ...
|
|
WO/2009/145263A1 |
Disclosed are a process suited to large scale synthesis with high yield for producing oseltamivir phosphate, in which a preparation of oseltamivir phosphate which is highly safe as a pharmaceutical product can be produced, and an interme...
|
|
WO/2009/142967A1 |
Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, an...
|
|
WO/2009/142194A1 |
Disclosed is a production method which enables mass synthesis of an aminoalcohol derivative with high optical purity at low cost. For example, a compound represented by the general formula is recrystallized during the production procedur...
|
|
WO/2009/141984A1 |
Disclosed is a metal compound represented by general formula (0). (In general formula (0), A represents a thietane ring or a monovalent group containing a thiol group; B represents a divalent group containing a heteroatom; R2 represents ...
|
|
WO/2009/138436A1 |
The invention relates to novel compounds of the formula (I) R1NH-CH(R2)-CH2-S- S-CH2-C(R3)(R4)-CONH-C(R5)(R6)-COOR7, in which R1 is a (acyloxy)alkyl carbamate -C(O)-O-C(R8)(R9)-OC(O)-R10 group; R2 is a hydrocarbon chain, a methylene radi...
|
|
WO/2009/135590A1 |
The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors...
|
|
WO/2003/096987A9 |
|
|
WO/2009/135526A1 |
Substituted amides of the general formula (I): with the residues A, R1 and R2 as explained in detail in the description are described. The compounds are suitable in particular as neutral endopeptidase inhibitors and are highly potent.
|
|
WO/2009/137251A2 |
The present invention provides cysteine and cystine bioisosteres for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing such bioisosteres and methods of using the b...
|
|
WO/2009/132832A2 |
The invention relates to a method for producing 1,4-benzothiepin-1,1-dioxide derivatives substituted with benzyl groups.
|
|
WO/2009/131189A1 |
Provided are a ketoxime ester compound which can be used as a novel and highly sensitive photopolymerization initiator; and a photopolymerizable composition useful for an interlayer insulating film and a color filter with high sensitivit...
|
